Home > Cardiology > ACC 2019 > Vascular Medicine > Lower rates stroke/SE with DOACs in frail non-valvular AF patients

Lower rates stroke/SE with DOACs in frail non-valvular AF patients

Expert
Prof. Gregory Lip, University of Birmingham, United Kingdom
Conference
ACC 2019

Results suggest that DOACs are associated with lower rates of stroke/systemic embolism (SE) and varying rates of major bleeding compared with warfarin in frail non-valvular atrial fibrillation (AF) patients [1].

AF is the most common arrhythmia in the elderly, and it is an independent risk factor for stroke [2]. Also, the prevalence of frailty increases steadily with age, from approximately 4% at 65-69 years of age to nearly 26% at 85 years or above [3]. It is estimated that non-valvular AF patients have a 4-times higher odds of being classified as frail than patients without non-valvular AF [4], and despite the high prevalence of AF among frail elderly patients, fewer frail AF patients receive oral coagulants compared with non-frail patients [5,6]. Even so, very few real-world studies have examined the comparative efficacy and safety outcomes between non-vitamin K antagonist oral coagulants (DOACs) and warfarin in the frail elderly non-valvular AF populat...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on